AT101 for relapsed or refractory B-cell lymphoma patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell non-Hodgkin lymphoma diagnosed by the standard WHO 2017 system
- Your lymphoma is relapsed or refractory, or standard treatments don’t work for you or can’t be used
- Your health status is good enough (ECOG performance status 0 or 1)
- Your blood counts and organ function (kidney, liver, lungs, heart, and bone marrow) are adequate, without needing a transfusion in the last 2 weeks
- You can stay well enough for at least 12 weeks (life expectancy ≥12 weeks)
- If you can become pregnant, pregnancy tests are negative and you can follow the trial contraception rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This trial tests a new treatment called ALA-101 for people with certain types of blood cancers (lymphoma and leukemia) that have a protein on the cancer cells called CD19. The treatment aims to target and destroy these cancer cells, potentially helping patients who have not responded to other therapies.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.